N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]acetamide | 1037211-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]acetamide
• CAS: 1037211-68-9
• 化学式: C₃₀H₄₈N₂O₂
• 分子量: 468.723
• InChiKey: LDQURTUYILCCDN-ZUTZEPCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  34
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 氢气 作用下， 以 异丙醇 为溶剂， 反应 16.0h， 以185 mg的产率得到N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]acetamide
  参考文献：
  名称：

  Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

  摘要：

  Recent evidence suggests that blocking aberrant hedgehog pathway signaling may be a promising therapeutic strategy for the treatment of several types of cancer. Cyclopamine, a plant Veratrum alkaloid, is a natural product antagonist of the hedgehog pathway. In a previous report, a seven-membered D-ring semisynthetic analogue of cyclopamine, IPI-269609 (2), was shown to have greater acid stability and better aqueous solubility compared to cyclopamine. Further modifications of the A-ring system generated three series of analogues with improved potency and/or Solubility. Lead compounds from each series were characterized in vitro and evaluated in vivo for biological activity and pharmacokinetic properties. These studies led to the discovery of IPI-926 (compound 28), a novel semisynthetic cyclopamine analogue with substantially improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and compound 2. As a result, complete tumor regression was observed in a Hh-dependent medulloblastoma allograft model after daily oral administration of 40 mg/kg of compound 28.

  DOI：

  10.1021/jm900305z

文献信息

• Peptide-based multimeric targeted contrast agents
  申请人：Zhang Zhaoda

  公开号：US20050074411A1

  公开（公告）日：2005-04-07

  Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

  本文描述了肽和肽靶向多聚对比剂，以及制备和使用对比剂的方法。
• Cyclopamine analogs
  申请人：Infinity Discovery, Inc.

  公开号：EP2443926A2

  公开（公告）日：2012-04-25

  The invention provides novel derivatives of cyclopamine having the following formula: wherein the nature of the moieties R1, R2, R3, R4, R7, R7', R8 and R9 is defined in appended claim 1.

  本发明提供了具有下式的环丙胺新型衍生物： 其中分子 R1、R2、R3、R4、R7、R7'、R8 和 R9 的性质在所附权利要求 1 中定义。
• Methods of use of cyclopamine analogs
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US10314827B2

  公开（公告）日：2019-06-11

  The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:

  本发明提供了使用具有下式的环丙胺衍生物治疗各种疾病的方法：
• CYCLOPAMINE ANALOGS
  申请人：Austad Brian

  公开号：US20080293754A1

  公开（公告）日：2008-11-27

  The invention provides novel derivatives of cyclopamine having the following formula:
• THERAPEUTIC CANCER TREATMENTS
  申请人：GRAYZEL David

  公开号：US20090181997A1

  公开（公告）日：2009-07-16

  The invention is directed to use of hedgehog inhibitors in conjunction with chemotherapy in treating cancers, and preventing relapses thereby.